Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Summary
The purpose of this phase I trial is to evaluate the maximum tolerated dose and safety of the ERK inhibitor BVD-523 at the recommended phase II dose in combination with nab-paclitaxel plus gemcitabine in patients with newly diagnosed metastatic pancreatic cancer.
General Information
NCT#: NCT02608229
Study ID: 15-x384
Trial Phase: Phase I
Trial Sponsor: Washington University, BioMed Valley Discoveries
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Ulixertinib